+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Male Infertility Diagnosis and Treatment Market 2019-2025

  • ID: 4896963
  • Report
  • December 2019
  • Region: Global
  • Orion Market Research Private Limited
UP TO OFF
until Mar 31st 2020
1 of 3

FEATURED COMPANIES

  • Androvia LifeSciences
  • Bristol-Myers Squibb Co.
  • Cordex Pharma, Inc.
  • Merck KGaA
  • Pantarhei Bioscience B.V.
  • Sanofi S.A.
  • MORE
Male Infertility Diagnosis and Treatment Market Size, Share & Trends Analysis Report, By Diagnostic Tests (Semen Analysis, Urinalysis, Genetic Testing, Testicular Biopsy, Hormonal Tests and Others) By Treatment (Drugs, ART Therapy and Surgery) and Forecast, 2019-2025.

The global male infertility diagnosis and treatment market is anticipated to witness modest growth during the forecast period. The major factors augmenting the growth of the market include significant growth in infertility rates, lifestyle associated risk factors and advances in male infertility treatment. Alcohol consumption is estimated to be one of the unhealthy lifestyle habits that may contribute to a rise in male infertility cases. According to World Health Organization (WHO), Alcohol is consumed by more than half of the population in the Americas, Europe and the Western Pacific. Total alcohol per capita consumption in the global population over 15 years of age rose from 5.5 liters of pure alcohol in 2005 and reached at the level of 6.4 liters in 2016.

The highest levels of per capita alcohol consumption are observed in countries of the WHO European region. Heavy alcohol consumption among men may cause infertility as it can decrease the production of normally formed sperm by interfering with the functioning of the male reproductive system. It can disrupt testosterone levels that produce both sperm and testosterone. Both long- and short-term heavy alcohol consumption has been shown to decrease testosterone level which may lead to the rise in infertility rates. However, high-cost of infertility treatment is the major restraining factor for the market growth.

Based on the geography, the market is further analyzed on the basis of four major regions including North America, Europe, Asia-Pacific and RoW. North America is anticipated to hold the largest share in the market owing to significant awareness regarding infertility in the region. Furthermore, the rising incidences of infertility are also one of the major factors encouraging the growth of the market in the region. For instance, as per the US Department of Health and Human Services (HHS), out of 100 couples in the US, 12 to 13 have trouble conceiving. Of which, nearly one-third of infertility cases reported due to fertility problems in men in the US. Asia Pacific is anticipated to witness optimistic growth in the market owing to the rising awareness among the population for infertility treatment and significant growth in infertility centers in the region
The major players in the market include Merck KGaA, Halotech DNA SL, PerkinElmer, Inc., Vitrolife AB and Medical Electronic Systems. In order to survive in the market, these players are adopting crucial strategies, such as mergers and acquisitions, product launches, and partnerships and collaborations. This enables the company to increase its competitiveness and attract significant share in the market.

Research Methodology

The market study of the global male infertility diagnosis and treatment market is incorporated by extensive primary and secondary research. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders and industry experts. Primary research brings authenticity in our reports.

Secondary sources include:
  • Financial reports of companies involved in the market
  • Authentic public databases
  • Whitepapers, research-papers, and news blogs
  • Company websites and their product catalog
The report is intended for providers of in-vitro diagnostics tools, infertility diagnostic tests and treatment alternatives for overall market analysis and competitive analysis. The report provides in-depth analysis on market size, intended quality of the service preferred by consumers. The report will serve as a source for 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation:
  • Global Male Infertility Diagnosis and Treatment Market Research and Analysis, By Diagnostic Tests
  • Global Male Infertility Diagnosis and Treatment Market Research and Analysis, By Treatment
The Report covers:
  • Comprehensive research methodology of the global male infertility diagnosis and treatment market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • Exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the global male infertility diagnosis and treatment market.
  • Insights about market determinants which are stimulating the global male infertility diagnosis and treatment market.
  • Detailed and extensive market segments with regional distribution of forecast revenues.
  • Extensive profiles and recent developments of market players.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Androvia LifeSciences
  • Bristol-Myers Squibb Co.
  • Cordex Pharma, Inc.
  • Merck KGaA
  • Pantarhei Bioscience B.V.
  • Sanofi S.A.
  • MORE
1. Report Summary
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Geography
1.2.3. By Stakeholders

2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
2.3. Rules & Regulations

3. Competitive Landscape
3.1. Competitive Dashboard
3.2. Key Strategy Analysis
3.3. Key Company Analysis
3.3.1. Merck KGaA
3.3.1.1. Overview
3.3.1.2. Financial Analysis
3.3.1.3. SWOT Analysis
3.3.1.4. Recent Developments
3.3.2. Halotech DNA SL
3.3.2.1. Overview
3.3.2.2. Financial Analysis
3.3.2.3. SWOT Analysis
3.3.2.4. Recent Developments
3.3.3. PerkinElmer, Inc.
3.3.3.1. Overview
3.3.3.2. Financial Analysis
3.3.3.3. SWOT Analysis
3.3.3.4. Recent Developments
3.3.4. Vitrolife AB
3.3.4.1. Overview
3.3.4.2. Financial Analysis
3.3.4.3. SWOT Analysis
3.3.4.4. Recent Developments
3.3.5. Medical Electronic Systems
3.3.5.1. Overview
3.3.5.2. Financial Analysis
3.3.5.3. SWOT Analysis
3.3.5.4. Recent Developments

4. Market Determinants
4.1. Motivators
4.2. Restraints
4.3. Opportunities

5. Market Segmentation
5.1. Global Male Infertility Diagnosis and Treatment Market by Diagnostic Tests
5.1.1. Semen Analysis
5.1.2. Urinalysis
5.1.3. Genetic Testing
5.1.4. Testicular Biopsy
5.1.5. Hormonal Tests
5.1.6. Others (Anti-sperm Antibodies Test and Ultrasound)
5.2. Global Male Infertility Diagnosis and Treatment Market by Treatment
5.2.1.1. Drugs
5.2.1.2. ART Therapy
5.2.1.3. Surgery

6. Regional Analysis
6.1. North America
6.1.1. US
6.1.2. Canada
6.2. Europe
6.2.1. UK
6.2.2. Germany
6.2.3. Italy
6.2.4. Spain
6.2.5. France
6.2.6. Rest of Europe
6.3. Asia-Pacific
6.3.1. China
6.3.2. India
6.3.3. Japan
6.3.4. Rest of Asia-Pacific
6.4. Rest of the World

7. Company Profiles
7.1. Androvia LifeSciences
7.2. ASKA Pharmaceutical Co., Ltd.
7.3. Aytu BioScience, Inc.
7.4. Bayer AG
7.5. Bristol-Myers Squibb Co.
7.6. Cadila Pharmaceuticals Ltd.
7.7. Centogene AG
7.8. Cook Medical, Inc.
7.9. CooperSurgical Fertility & Genomic Solutions
7.10. Cordex Pharma, Inc.
7.11. Eli Lilly and Co.
7.12. FUJIFILM Irvine Scientific
7.13. Halotech DNA SL
7.14. Intas pharmaceuticals Ltd.
7.15. Medical Electronic Systems
7.16. Merck KGaA
7.17. Microm UK Ltd.
7.18. myLAB
7.19. Pantarhei Bioscience B.V.
7.20. PerkinElmer, Inc.
7.21. Pfizer, Inc.
7.22. Sanofi S.A.
7.23. SCSA Diagnostics, Inc.
7.24. Vitrolife AB
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Androvia LifeSciences
  • ASKA Pharmaceutical Co., Ltd.
  • Aytu BioScience, Inc.
  • Bayer AG
  • Bristol-Myers Squibb Co.
  • Cadila Pharmaceuticals Ltd.
  • Centogene AG
  • Cook Medical, Inc.
  • CooperSurgical Fertility & Genomic Solutions
  • Cordex Pharma, Inc.
  • Eli Lilly and Co.
  • FUJIFILM Irvine Scientific
  • Halotech DNA SL
  • Intas pharmaceuticals Ltd.
  • Medical Electronic Systems
  • Merck KGaA
  • Microm UK Ltd.
  • myLAB
  • Pantarhei Bioscience B.V.
  • PerkinElmer, Inc.
  • Pfizer, Inc.
  • Sanofi S.A.
  • SCSA Diagnostics, Inc.
  • Vitrolife AB
Note: Product cover images may vary from those shown
Adroll
adroll